Holen Sie sich die Stockscreener-App
26.33
0.15%
-0.04
Handel nachbörslich:
26.09
-0.24
-0.91%
Damora Therapeutics Inc Aktie (DMRA) Neueste Nachrichten
Taxes of Damora Therapeutics, Inc. – NASDAQ:DMRA - TradingView
Damora Therapeutics, Inc. Statistics – NASDAQ:DMRA - TradingView
Damora Therapeutics, Inc. Earnings and Revenue – NASDAQ:DMRA - TradingView
Total assets of Damora Therapeutics, Inc. – NASDAQ:DMRA - TradingView
Galecto Changes Name to Damora Therapeutics, Advances mutCALR Antibody Pipeline for Blood Disorders and Secures $535M Funding 1 - Minichart
Galecto Rebrands as Damora Therapeutics with New Ticker - TipRanks
Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders - Bitget
Galecto (GLTO) Rebrands to Damora Therapeutics, Plans Nasdaq Lis - GuruFocus
Galecto rebrands as Damora Therapeutics, begins Nasdaq trading - Investing.com
Damora Therapeutics holds $535M cash to target rare blood cancers - Stock Titan
Galecto Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - marketscreener.com
Galecto announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Biotech brings in cancer drug veterans as it readies new antibody trial - Stock Titan
Mintz Advises Galecto, Inc. in its acquisition of Damora Therapeutics, Inc. and its concurrent $285 million private placement - Mintz
US: Galecto acquires Damora Tx and raises US$285m from Series C - Investors in Healthcare
Galecto Stock Surges Premarket After Damora Acquisition — Retail Bulls Predict Another Massive Rally - Stocktwits
A Week Is A Long Time In Biotech, Just Ask Galecto - Citeline News & Insights
Galecto, Inc. (GLTO) Stock: Rockets After $284.9M Funding Boost and Strategic Damora Acquisition - parameter.io
Galecto Reports First Quarter 2025 Operating and Financial Results - marketscreener.com
GLTO Stock Price, News & Analysis - Stock Titan
Galecto to Participate in Upcoming Investor Conferences - marketscreener.com
Galecto Reports Third Quarter 2024 Financial Results - marketscreener.com
Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler - marketscreener.com
Galecto Announces Reverse Stock Split - marketscreener.com
Galecto to Present at Investor Conferences in September - marketscreener.com
Galecto Set to Join Russell Microcap® Index - marketscreener.com
Galecto to Participate in Oppenheimer’s 33rd Annual Healthcare Conference - marketscreener.com
Galecto to Participate in SVB Securities Global Biopharma Conference - marketscreener.com
GALECTO, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - marketscreener.com
Galecto to Take Part in Two Panel Discussions at the LifeSci Partners 10th Annual Healthcare Corporate Access Event - marketscreener.com
Galecto, Inc. Appoints Dr. Jayson Dallas to Board of Directors - marketscreener.com
DMRA Stock Price and Chart — NASDAQ:DMRA - TradingView
Galecto Biotech AB Appoints Richard Marshall as Chief Medical Officer - marketscreener.com
0.48%
1.21%
Kapitalisierung:
|
Volumen (24h):